Q-omics provides the consensus-scored IFI35 profile across patient tissues and cancer cell-line models. IFI35 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, IFI35 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, IFI35 protein abundance shows 21,326 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, HNSC, and GBM as cancer lineages where IFI35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IFI35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IFI35 survival associations across molecular data types. IFI35 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IFI35 RNA expression–survival associations across cancer types. High IFI35 expression shows unfavorable associations in UVM, PAAD, KIRC and LGG, but favorable associations in SKCM and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for IFI35 RNA expression.
This table summarizes IFI35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for IFI35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IFI35 shows lower tumor expression in KICH, UCEC and LUSC and higher tumor expression in HNSC, KIRC and KIRP. The HNSC box plot shows higher IFI35 RNA expression in tumor versus normal tissue (log2 FC = +1.728, t-test p < 0.001).
This table shows molecular features associated with IFI35 in patient tissues and cancer cell lines. In patient samples, IFI35 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, IFI35 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SOFT_TISSUE.
